Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, Bristol Myers Squibb Presents Phase 1 Breakfree-1 Data Showing CD19 NEX-T CAR T Therapy Achieves 94% Off Immunosuppressive Therapy In Autoimmune Diseases

Author: Benzinga Newsdesk | October 27, 2025 01:55am

Positive, early results from 71 patients treated across three disease cohorts – systemic sclerosis, systemic lupus erythematosus and idiopathic inflammatory myopathies – are being disclosed
Across all cohorts, results support potential for immune reset, with 94% of evaluable patients remaining off chronic immunosuppressive therapy at the time of analysis
Results demonstrate BMS' steady advancement toward its goal of bringing the science of cell therapy beyond blood cancer into autoimmune diseases

Posted In: BMY